CLTC and GGA1 |
clathrin heavy chain |
golgi associated, gamma adaptin ear containing, ARF binding protein 1 |
- Entry of Influenza Virion into Host Cell via Endocytosis
- Retrograde neurotrophin signalling
- Retrograde neurotrophin signalling
- Gap junction degradation
- Formation of annular gap junctions
- MHC class II antigen presentation
- EPH-ephrin mediated repulsion of cells
- Lysosome Vesicle Biogenesis
- Recycling pathway of L1
- Recycling pathway of L1
- WNT5A-dependent internalization of FZD4
- WNT5A-dependent internalization of FZD2, FZD5 and ROR2
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- VLDLR internalisation and degradation
- LDL clearance
|
- TBC/RABGAPs
- Amyloid fiber formation
|
|
|
|
|
CLTC and XRCC6 |
clathrin heavy chain |
X-ray repair cross complementing 6 |
- Entry of Influenza Virion into Host Cell via Endocytosis
- Retrograde neurotrophin signalling
- Retrograde neurotrophin signalling
- Gap junction degradation
- Formation of annular gap junctions
- MHC class II antigen presentation
- EPH-ephrin mediated repulsion of cells
- Lysosome Vesicle Biogenesis
- Recycling pathway of L1
- Recycling pathway of L1
- WNT5A-dependent internalization of FZD4
- WNT5A-dependent internalization of FZD2, FZD5 and ROR2
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- VLDLR internalisation and degradation
- LDL clearance
|
- 2-LTR circle formation
- Cytosolic sensors of pathogen-associated DNA
- IRF3-mediated induction of type I IFN
- Nonhomologous End-Joining (NHEJ)
- Neutrophil degranulation
|
|
|
|
|
CLTC and SNX5 |
clathrin heavy chain |
sorting nexin 5 |
- Entry of Influenza Virion into Host Cell via Endocytosis
- Retrograde neurotrophin signalling
- Retrograde neurotrophin signalling
- Gap junction degradation
- Formation of annular gap junctions
- MHC class II antigen presentation
- EPH-ephrin mediated repulsion of cells
- Lysosome Vesicle Biogenesis
- Recycling pathway of L1
- Recycling pathway of L1
- WNT5A-dependent internalization of FZD4
- WNT5A-dependent internalization of FZD2, FZD5 and ROR2
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- VLDLR internalisation and degradation
- LDL clearance
|
- Golgi Associated Vesicle Biogenesis
|
|
|
|
|
COL1A1 and MMP9 |
collagen type I alpha 1 chain |
matrix metallopeptidase 9 |
- GPVI-mediated activation cascade
- Collagen degradation
- Collagen degradation
- Extracellular matrix organization
- Collagen biosynthesis and modifying enzymes
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
- Assembly of collagen fibrils and other multimeric structures
- Cell surface interactions at the vascular wall
- Integrin cell surface interactions
- Integrin cell surface interactions
- Anchoring fibril formation
- Crosslinking of collagen fibrils
- Syndecan interactions
- Non-integrin membrane-ECM interactions
- ECM proteoglycans
- ECM proteoglycans
- Scavenging by Class A Receptors
- GP1b-IX-V activation signalling
- Platelet Adhesion to exposed collagen
- Platelet Adhesion to exposed collagen
- Platelet Aggregation (Plug Formation)
- MET activates PTK2 signaling
- RUNX2 regulates osteoblast differentiation
- Collagen chain trimerization
|
- Signaling by SCF-KIT
- Collagen degradation
- Collagen degradation
- Degradation of the extracellular matrix
- Degradation of the extracellular matrix
- Activation of Matrix Metalloproteinases
- Assembly of collagen fibrils and other multimeric structures
- EPH-ephrin mediated repulsion of cells
- Interleukin-4 and Interleukin-13 signaling
- Neutrophil degranulation
- Extra-nuclear estrogen signaling
|
- Collagenase clostridium histolyticum
- Halofuginone
|
- Glutathione
- Marimastat
- Minocycline
- Captopril
- Glucosamine
- Zinc
- 2-Amino-N,3,3-Trimethylbutanamide
- 2-{[Formyl(Hydroxy)Amino]Methyl}-4-Methylpentanoic Acid
- AE-941
- PG-530742
- 5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE
- (2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE
- (3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACID
|
- Ehlers-Danlos syndrome (EDS), including: EDS classical type (EDS1/2); EDS hypermobility type (EDS3); EDS vascular type (EDS4); EDS kyphoscoliosis type (EDS6); EDS arthrochalasia type (EDS7A/7B); EDS dermatospraxis type (EDS7C); EDS autosomal recessive cardiac valvular form (EDSCV); EDS musculocontractural type (EDSMC); EDS progeroid form (EDSP); Tenascin-X deficiency (TNXD); Brittle cornea syndrome (EDS6B); EDS-like spondylocheiro dysplasia (SCD-EDS)
- Infantile cortical hyperostosis; Caffey disease
- Osteogenesis imperfecta
|
- Penile cancer
- Metaphyseal dysplasias, including: Metaphyseal dysplasia, Schmid type; Metaphyseal dysplasia, McKusik type; Metaphyseal dysplasia, Jansen type; Shwachman-Bodian-Diamond syndrome (SBDS); Metaphyseal anadysplasia (MAD)
|
COL1A2 and MMP9 |
collagen type I alpha 2 chain |
matrix metallopeptidase 9 |
- GPVI-mediated activation cascade
- Collagen degradation
- Collagen degradation
- Extracellular matrix organization
- Collagen biosynthesis and modifying enzymes
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
- Assembly of collagen fibrils and other multimeric structures
- Cell surface interactions at the vascular wall
- Integrin cell surface interactions
- Integrin cell surface interactions
- Anchoring fibril formation
- Crosslinking of collagen fibrils
- Syndecan interactions
- Non-integrin membrane-ECM interactions
- ECM proteoglycans
- ECM proteoglycans
- Scavenging by Class A Receptors
- GP1b-IX-V activation signalling
- Interleukin-4 and Interleukin-13 signaling
- Platelet Adhesion to exposed collagen
- Platelet Adhesion to exposed collagen
- Platelet Aggregation (Plug Formation)
- MET activates PTK2 signaling
- Collagen chain trimerization
|
- Signaling by SCF-KIT
- Collagen degradation
- Collagen degradation
- Degradation of the extracellular matrix
- Degradation of the extracellular matrix
- Activation of Matrix Metalloproteinases
- Assembly of collagen fibrils and other multimeric structures
- EPH-ephrin mediated repulsion of cells
- Interleukin-4 and Interleukin-13 signaling
- Neutrophil degranulation
- Extra-nuclear estrogen signaling
|
- Collagenase clostridium histolyticum
|
- Glutathione
- Marimastat
- Minocycline
- Captopril
- Glucosamine
- Zinc
- 2-Amino-N,3,3-Trimethylbutanamide
- 2-{[Formyl(Hydroxy)Amino]Methyl}-4-Methylpentanoic Acid
- AE-941
- PG-530742
- 5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE
- (2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE
- (3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACID
|
- Ehlers-Danlos syndrome (EDS), including: EDS classical type (EDS1/2); EDS hypermobility type (EDS3); EDS vascular type (EDS4); EDS kyphoscoliosis type (EDS6); EDS arthrochalasia type (EDS7A/7B); EDS dermatospraxis type (EDS7C); EDS autosomal recessive cardiac valvular form (EDSCV); EDS musculocontractural type (EDSMC); EDS progeroid form (EDSP); Tenascin-X deficiency (TNXD); Brittle cornea syndrome (EDS6B); EDS-like spondylocheiro dysplasia (SCD-EDS)
- Osteogenesis imperfecta
|
- Penile cancer
- Metaphyseal dysplasias, including: Metaphyseal dysplasia, Schmid type; Metaphyseal dysplasia, McKusik type; Metaphyseal dysplasia, Jansen type; Shwachman-Bodian-Diamond syndrome (SBDS); Metaphyseal anadysplasia (MAD)
|
COL2A1 and TGFB1 |
collagen type II alpha 1 chain |
transforming growth factor beta 1 |
- Collagen degradation
- Collagen degradation
- Extracellular matrix organization
- Collagen biosynthesis and modifying enzymes
- Signaling by PDGF
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
- Assembly of collagen fibrils and other multimeric structures
- Integrin cell surface interactions
- Integrin cell surface interactions
- Non-integrin membrane-ECM interactions
- ECM proteoglycans
- ECM proteoglycans
- NCAM1 interactions
- MET activates PTK2 signaling
- Collagen chain trimerization
|
- Platelet degranulation
- Influenza Virus Induced Apoptosis
- Cell surface interactions at the vascular wall
- Molecules associated with elastic fibres
- Downregulation of TGF-beta receptor signaling
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- Syndecan interactions
- ECM proteoglycans
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- TGFBR1 KD Mutants in Cancer
- TGFBR1 LBD Mutants in Cancer
- Transcriptional regulation of white adipocyte differentiation
- UCH proteinases
- Interleukin-4 and Interleukin-13 signaling
- RUNX3 regulates CDKN1A transcription
- Regulation of RUNX3 expression and activity
- RUNX3 regulates p14-ARF
|
- Collagenase clostridium histolyticum
|
- Hyaluronidase
- Hyaluronidase (Human Recombinant)
|
- Type II collagenopathies, including: Achondrogenesis II; Hypochondrogenesis; SED congenita; SMED Strudwick type; Kniest dysplasia; Spondyloperipheral dysplasia; Osteoarthritis with mild chondrodysplasia; Stickler syndrome 1; Platyspondylic skeletal dysplasia, Torrance type; Epiphyseal dysplasia, multiple, with myopia and deafness; Czech dysplasia
- Vitreoretinal degeneration, including: Stickler syndrome type I (STL1); Stickler syndrome type II (STL2); Snowflake vitreoretinal degeneration (SVD); Wagner syndrome 1 (WGN1); Knobloch syndrome (KNO); Enhanced S-cone syndrome (ESCS); Autosomal dominant vitreoretinochoroidopathy (ADVIRC)
- Osteoarthritis with mild chondrodysplasia
|
- Graft-versus-host disease
- Allograft rejection
- Camurati-Engelmann disease; Progressive diaphyseal dysplasia
|
COL4A1 and MMP9 |
collagen type IV alpha 1 chain |
matrix metallopeptidase 9 |
- Collagen degradation
- Collagen degradation
- Extracellular matrix organization
- Collagen biosynthesis and modifying enzymes
- Signaling by PDGF
- Assembly of collagen fibrils and other multimeric structures
- Integrin cell surface interactions
- Integrin cell surface interactions
- Anchoring fibril formation
- Crosslinking of collagen fibrils
- Laminin interactions
- Laminin interactions
- Non-integrin membrane-ECM interactions
- ECM proteoglycans
- Scavenging by Class A Receptors
- NCAM1 interactions
- Collagen chain trimerization
|
- Signaling by SCF-KIT
- Collagen degradation
- Collagen degradation
- Degradation of the extracellular matrix
- Degradation of the extracellular matrix
- Activation of Matrix Metalloproteinases
- Assembly of collagen fibrils and other multimeric structures
- EPH-ephrin mediated repulsion of cells
- Interleukin-4 and Interleukin-13 signaling
- Neutrophil degranulation
- Extra-nuclear estrogen signaling
|
|
- Glutathione
- Marimastat
- Minocycline
- Captopril
- Glucosamine
- Zinc
- 2-Amino-N,3,3-Trimethylbutanamide
- 2-{[Formyl(Hydroxy)Amino]Methyl}-4-Methylpentanoic Acid
- AE-941
- PG-530742
- 5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE
- (2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE
- (3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACID
|
- Brain small vessel disease with Axenfeld-Rieger anomaly
- Porencephaly
- Hereditary angiopathy with nephropathy, aneurysms, and muscle cramps (HANAC)
|
- Penile cancer
- Metaphyseal dysplasias, including: Metaphyseal dysplasia, Schmid type; Metaphyseal dysplasia, McKusik type; Metaphyseal dysplasia, Jansen type; Shwachman-Bodian-Diamond syndrome (SBDS); Metaphyseal anadysplasia (MAD)
|
COL4A2 and MMP9 |
collagen type IV alpha 2 chain |
matrix metallopeptidase 9 |
- Collagen degradation
- Collagen degradation
- Extracellular matrix organization
- Collagen biosynthesis and modifying enzymes
- Signaling by PDGF
- Assembly of collagen fibrils and other multimeric structures
- Integrin cell surface interactions
- Integrin cell surface interactions
- Anchoring fibril formation
- Crosslinking of collagen fibrils
- Laminin interactions
- Laminin interactions
- Non-integrin membrane-ECM interactions
- ECM proteoglycans
- Scavenging by Class A Receptors
- NCAM1 interactions
- Collagen chain trimerization
|
- Signaling by SCF-KIT
- Collagen degradation
- Collagen degradation
- Degradation of the extracellular matrix
- Degradation of the extracellular matrix
- Activation of Matrix Metalloproteinases
- Assembly of collagen fibrils and other multimeric structures
- EPH-ephrin mediated repulsion of cells
- Interleukin-4 and Interleukin-13 signaling
- Neutrophil degranulation
- Extra-nuclear estrogen signaling
|
|
- Glutathione
- Marimastat
- Minocycline
- Captopril
- Glucosamine
- Zinc
- 2-Amino-N,3,3-Trimethylbutanamide
- 2-{[Formyl(Hydroxy)Amino]Methyl}-4-Methylpentanoic Acid
- AE-941
- PG-530742
- 5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE
- (2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE
- (3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACID
|
|
- Penile cancer
- Metaphyseal dysplasias, including: Metaphyseal dysplasia, Schmid type; Metaphyseal dysplasia, McKusik type; Metaphyseal dysplasia, Jansen type; Shwachman-Bodian-Diamond syndrome (SBDS); Metaphyseal anadysplasia (MAD)
|
COL4A3 and MMP9 |
collagen type IV alpha 3 chain |
matrix metallopeptidase 9 |
- Collagen degradation
- Collagen degradation
- Extracellular matrix organization
- Collagen biosynthesis and modifying enzymes
- Signaling by PDGF
- Assembly of collagen fibrils and other multimeric structures
- Integrin cell surface interactions
- Integrin cell surface interactions
- Anchoring fibril formation
- Crosslinking of collagen fibrils
- Laminin interactions
- Laminin interactions
- Non-integrin membrane-ECM interactions
- ECM proteoglycans
- NCAM1 interactions
- Collagen chain trimerization
|
- Signaling by SCF-KIT
- Collagen degradation
- Collagen degradation
- Degradation of the extracellular matrix
- Degradation of the extracellular matrix
- Activation of Matrix Metalloproteinases
- Assembly of collagen fibrils and other multimeric structures
- EPH-ephrin mediated repulsion of cells
- Interleukin-4 and Interleukin-13 signaling
- Neutrophil degranulation
- Extra-nuclear estrogen signaling
|
|
- Glutathione
- Marimastat
- Minocycline
- Captopril
- Glucosamine
- Zinc
- 2-Amino-N,3,3-Trimethylbutanamide
- 2-{[Formyl(Hydroxy)Amino]Methyl}-4-Methylpentanoic Acid
- AE-941
- PG-530742
- 5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE
- (2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE
- (3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACID
|
- Benign familial hematuria; Thin basement membrane nephropathy
- Alport syndrome
|
- Penile cancer
- Metaphyseal dysplasias, including: Metaphyseal dysplasia, Schmid type; Metaphyseal dysplasia, McKusik type; Metaphyseal dysplasia, Jansen type; Shwachman-Bodian-Diamond syndrome (SBDS); Metaphyseal anadysplasia (MAD)
|
COL4A4 and MMP9 |
collagen type IV alpha 4 chain |
matrix metallopeptidase 9 |
- Collagen degradation
- Collagen degradation
- Extracellular matrix organization
- Collagen biosynthesis and modifying enzymes
- Signaling by PDGF
- Assembly of collagen fibrils and other multimeric structures
- Integrin cell surface interactions
- Integrin cell surface interactions
- Anchoring fibril formation
- Crosslinking of collagen fibrils
- Laminin interactions
- Laminin interactions
- Non-integrin membrane-ECM interactions
- ECM proteoglycans
- NCAM1 interactions
- Collagen chain trimerization
|
- Signaling by SCF-KIT
- Collagen degradation
- Collagen degradation
- Degradation of the extracellular matrix
- Degradation of the extracellular matrix
- Activation of Matrix Metalloproteinases
- Assembly of collagen fibrils and other multimeric structures
- EPH-ephrin mediated repulsion of cells
- Interleukin-4 and Interleukin-13 signaling
- Neutrophil degranulation
- Extra-nuclear estrogen signaling
|
|
- Glutathione
- Marimastat
- Minocycline
- Captopril
- Glucosamine
- Zinc
- 2-Amino-N,3,3-Trimethylbutanamide
- 2-{[Formyl(Hydroxy)Amino]Methyl}-4-Methylpentanoic Acid
- AE-941
- PG-530742
- 5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE
- (2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE
- (3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACID
|
- Benign familial hematuria; Thin basement membrane nephropathy
- Alport syndrome
|
- Penile cancer
- Metaphyseal dysplasias, including: Metaphyseal dysplasia, Schmid type; Metaphyseal dysplasia, McKusik type; Metaphyseal dysplasia, Jansen type; Shwachman-Bodian-Diamond syndrome (SBDS); Metaphyseal anadysplasia (MAD)
|
COL4A5 and MMP9 |
collagen type IV alpha 5 chain |
matrix metallopeptidase 9 |
- Collagen degradation
- Collagen degradation
- Extracellular matrix organization
- Collagen biosynthesis and modifying enzymes
- Signaling by PDGF
- Assembly of collagen fibrils and other multimeric structures
- Integrin cell surface interactions
- Integrin cell surface interactions
- Anchoring fibril formation
- Crosslinking of collagen fibrils
- Laminin interactions
- Laminin interactions
- Non-integrin membrane-ECM interactions
- ECM proteoglycans
- NCAM1 interactions
- Collagen chain trimerization
- Regulation of expression of SLITs and ROBOs
|
- Signaling by SCF-KIT
- Collagen degradation
- Collagen degradation
- Degradation of the extracellular matrix
- Degradation of the extracellular matrix
- Activation of Matrix Metalloproteinases
- Assembly of collagen fibrils and other multimeric structures
- EPH-ephrin mediated repulsion of cells
- Interleukin-4 and Interleukin-13 signaling
- Neutrophil degranulation
- Extra-nuclear estrogen signaling
|
|
- Glutathione
- Marimastat
- Minocycline
- Captopril
- Glucosamine
- Zinc
- 2-Amino-N,3,3-Trimethylbutanamide
- 2-{[Formyl(Hydroxy)Amino]Methyl}-4-Methylpentanoic Acid
- AE-941
- PG-530742
- 5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE
- (2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE
- (3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACID
|
|
- Penile cancer
- Metaphyseal dysplasias, including: Metaphyseal dysplasia, Schmid type; Metaphyseal dysplasia, McKusik type; Metaphyseal dysplasia, Jansen type; Shwachman-Bodian-Diamond syndrome (SBDS); Metaphyseal anadysplasia (MAD)
|
COL4A6 and MMP9 |
collagen type IV alpha 6 chain |
matrix metallopeptidase 9 |
- Collagen degradation
- Collagen degradation
- Extracellular matrix organization
- Collagen biosynthesis and modifying enzymes
- Assembly of collagen fibrils and other multimeric structures
- Integrin cell surface interactions
- Integrin cell surface interactions
- Anchoring fibril formation
- Crosslinking of collagen fibrils
- Laminin interactions
- Laminin interactions
- Non-integrin membrane-ECM interactions
- ECM proteoglycans
- Collagen chain trimerization
|
- Signaling by SCF-KIT
- Collagen degradation
- Collagen degradation
- Degradation of the extracellular matrix
- Degradation of the extracellular matrix
- Activation of Matrix Metalloproteinases
- Assembly of collagen fibrils and other multimeric structures
- EPH-ephrin mediated repulsion of cells
- Interleukin-4 and Interleukin-13 signaling
- Neutrophil degranulation
- Extra-nuclear estrogen signaling
|
|
- Glutathione
- Marimastat
- Minocycline
- Captopril
- Glucosamine
- Zinc
- 2-Amino-N,3,3-Trimethylbutanamide
- 2-{[Formyl(Hydroxy)Amino]Methyl}-4-Methylpentanoic Acid
- AE-941
- PG-530742
- 5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE
- (2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE
- (3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACID
|
|
- Penile cancer
- Metaphyseal dysplasias, including: Metaphyseal dysplasia, Schmid type; Metaphyseal dysplasia, McKusik type; Metaphyseal dysplasia, Jansen type; Shwachman-Bodian-Diamond syndrome (SBDS); Metaphyseal anadysplasia (MAD)
|
CREBBP and MAML2 |
CREB binding protein |
mastermind like transcriptional coactivator 2 |
- Regulation of gene expression by Hypoxia-inducible Factor
- RORA activates gene expression
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- Pre-NOTCH Transcription and Translation
- Pre-NOTCH Transcription and Translation
- PPARA activates gene expression
- PPARA activates gene expression
- Formation of the beta-catenin:TCF transactivating complex
- Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
- NOTCH1 Intracellular Domain Regulates Transcription
- NOTCH1 Intracellular Domain Regulates Transcription
- Transcriptional activation of mitochondrial biogenesis
- Activation of gene expression by SREBF (SREBP)
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
- HATs acetylate histones
- Attenuation phase
- Notch-HLH transcription pathway
- Transcriptional regulation of white adipocyte differentiation
- Transcriptional regulation of white adipocyte differentiation
- SUMOylation of transcription cofactors
- Regulation of lipid metabolism by PPARalpha
- Circadian Clock
- Activation of anterior HOX genes in hindbrain development during early embryogenesis
- CD209 (DC-SIGN) signaling
- TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
- Activation of the TFAP2 (AP-2) family of transcription factors
- RUNX1 regulates transcription of genes involved in differentiation of myeloid cells
- RUNX3 regulates NOTCH signaling
- RUNX3 regulates NOTCH signaling
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH4 Intracellular Domain Regulates Transcription
- Estrogen-dependent gene expression
- TRAF3-dependent IRF activation pathway
- TRAF6 mediated IRF7 activation
- FOXO-mediated transcription of cell death genes
- Regulation of FOXO transcriptional activity by acetylation
- Regulation of FOXO transcriptional activity by acetylation
|
- Pre-NOTCH Transcription and Translation
- Pre-NOTCH Transcription and Translation
- Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
- NOTCH1 Intracellular Domain Regulates Transcription
- NOTCH1 Intracellular Domain Regulates Transcription
- NOTCH2 intracellular domain regulates transcription
- NOTCH2 intracellular domain regulates transcription
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Notch-HLH transcription pathway
- RUNX3 regulates NOTCH signaling
- RUNX3 regulates NOTCH signaling
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH4 Intracellular Domain Regulates Transcription
- NOTCH4 Intracellular Domain Regulates Transcription
|
- 9-ACETYL-2,3,4,9-TETRAHYDRO-1H-CARBAZOL-1-ONE
|
|
- Rubinstein-Taybi syndrome
|
|
CREBBP and TFDP1 |
CREB binding protein |
transcription factor Dp-1 |
- Regulation of gene expression by Hypoxia-inducible Factor
- RORA activates gene expression
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- Pre-NOTCH Transcription and Translation
- Pre-NOTCH Transcription and Translation
- PPARA activates gene expression
- PPARA activates gene expression
- Formation of the beta-catenin:TCF transactivating complex
- Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
- NOTCH1 Intracellular Domain Regulates Transcription
- NOTCH1 Intracellular Domain Regulates Transcription
- Transcriptional activation of mitochondrial biogenesis
- Activation of gene expression by SREBF (SREBP)
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
- HATs acetylate histones
- Attenuation phase
- Notch-HLH transcription pathway
- Transcriptional regulation of white adipocyte differentiation
- Transcriptional regulation of white adipocyte differentiation
- SUMOylation of transcription cofactors
- Regulation of lipid metabolism by PPARalpha
- Circadian Clock
- Activation of anterior HOX genes in hindbrain development during early embryogenesis
- CD209 (DC-SIGN) signaling
- TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
- Activation of the TFAP2 (AP-2) family of transcription factors
- RUNX1 regulates transcription of genes involved in differentiation of myeloid cells
- RUNX3 regulates NOTCH signaling
- RUNX3 regulates NOTCH signaling
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH4 Intracellular Domain Regulates Transcription
- Estrogen-dependent gene expression
- TRAF3-dependent IRF activation pathway
- TRAF6 mediated IRF7 activation
- FOXO-mediated transcription of cell death genes
- Regulation of FOXO transcriptional activity by acetylation
- Regulation of FOXO transcriptional activity by acetylation
|
- Activation of NOXA and translocation to mitochondria
- Inhibition of replication initiation of damaged DNA by RB1/E2F1
- Transcription of E2F targets under negative control by DREAM complex
- Transcription of E2F targets under negative control by DREAM complex
- Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1
- Activation of PUMA and translocation to mitochondria
- G0 and Early G1
- Pre-NOTCH Transcription and Translation
- Pre-NOTCH Transcription and Translation
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Oxidative Stress Induced Senescence
- Oncogene Induced Senescence
- TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
- Cyclin E associated events during G1/S transition
- G1/S-Specific Transcription
- G1/S-Specific Transcription
- Cyclin D associated events in G1
- Cyclin A:Cdk2-associated events at S phase entry
- Transcriptional Regulation by E2F6
- Transcriptional regulation of granulopoiesis
- Transcriptional regulation of granulopoiesis
|
- 9-ACETYL-2,3,4,9-TETRAHYDRO-1H-CARBAZOL-1-ONE
|
|
- Rubinstein-Taybi syndrome
|
|
CRMP1 and DDX18 |
collapsin response mediator protein 1 |
DEAD-box helicase 18 |
- CRMPs in Sema3A signaling
|
|
|
|
|
|
HAPLN1 and MMP9 |
hyaluronan and proteoglycan link protein 1 |
matrix metallopeptidase 9 |
|
- Signaling by SCF-KIT
- Collagen degradation
- Collagen degradation
- Degradation of the extracellular matrix
- Degradation of the extracellular matrix
- Activation of Matrix Metalloproteinases
- Assembly of collagen fibrils and other multimeric structures
- EPH-ephrin mediated repulsion of cells
- Interleukin-4 and Interleukin-13 signaling
- Neutrophil degranulation
- Extra-nuclear estrogen signaling
|
|
- Glutathione
- Marimastat
- Minocycline
- Captopril
- Glucosamine
- Zinc
- 2-Amino-N,3,3-Trimethylbutanamide
- 2-{[Formyl(Hydroxy)Amino]Methyl}-4-Methylpentanoic Acid
- AE-941
- PG-530742
- 5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE
- (2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE
- (3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACID
|
|
- Penile cancer
- Metaphyseal dysplasias, including: Metaphyseal dysplasia, Schmid type; Metaphyseal dysplasia, McKusik type; Metaphyseal dysplasia, Jansen type; Shwachman-Bodian-Diamond syndrome (SBDS); Metaphyseal anadysplasia (MAD)
|
MAPK14 and MITF |
mitogen-activated protein kinase 14 |
melanocyte inducing transcription factor |
- NOD1/2 Signaling Pathway
- p38MAPK events
- p38MAPK events
- ERK/MAPK targets
- Activation of PPARGC1A (PGC-1alpha) by phosphorylation
- Oxidative Stress Induced Senescence
- DSCAM interactions
- ADP signalling through P2Y purinoceptor 1
- Platelet sensitization by LDL
- VEGFA-VEGFR2 Pathway
- activated TAK1 mediates p38 MAPK activation
- Activation of the AP-1 family of transcription factors
- KSRP (KHSRP) binds and destabilizes mRNA
- Myogenesis
- Myogenesis
- RHO GTPases Activate NADPH Oxidases
- Neutrophil degranulation
- Regulation of TP53 Activity through Phosphorylation
- CD163 mediating an anti-inflammatory response
|
- SUMOylation of transcription factors
|
- Dasatinib
- 4-[5-[2-(1-Phenyl-Ethylamino)-Pyrimidin-4-Yl]-1-Methyl-4-(3-Trifluoromethylphenyl)-1h-Imidazol-2-Yl]-Piperidine
- N-[(3z)-5-Tert-Butyl-2-Phenyl-1,2-Dihydro-3h-Pyrazol-3-Ylidene]-N'-(4-Chlorophenyl)Urea
- 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One
- Inhibitor of P38 Kinase
- 6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine
- 3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine
- 1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea
- 3-(Benzyloxy)Pyridin-2-Amine
- 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One
- 4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline
- 1-(5-Tert-Butyl-2-P-Tolyl-2h-Pyrazol-3-Yl)-3-[4-(2-Morpholin-4-Yl-Ethoxy)-Naphthalen-1-Yl]-Urea
- 2-Chlorophenol
- 4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole
- SB220025
- 4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE
- Triazolopyridine
- KC706
- Talmapimod
- VX-702
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
- N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide
- N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide
- Neflamapimod
- N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide
- 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE
- 4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE
- N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide
- 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE
- 4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde
- N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide
- N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide
- N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide
- PH-797804
- 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine
- 2-{4-[5-(4-chlorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-3-yl]piperidin-1-yl}-2-oxoethanol
- N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA
- N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO-
- 3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE
- 3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide
- 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE
- 3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA
- 8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM
- 2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE
- N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide
- N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide
- N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide
- 6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine
- 2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE
- [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE
- [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE
- 4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE
- 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE
- 3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE
|
|
|
- Ocular albinism; Ocular albinism, type I (OA1); Waardenburg syndrome, type II (WS2-OA)
- Waardenburg syndrome (WS)
- Malignant melanoma
|
MAPK14 and GATA3 |
mitogen-activated protein kinase 14 |
GATA binding protein 3 |
- NOD1/2 Signaling Pathway
- p38MAPK events
- p38MAPK events
- ERK/MAPK targets
- Activation of PPARGC1A (PGC-1alpha) by phosphorylation
- Oxidative Stress Induced Senescence
- DSCAM interactions
- ADP signalling through P2Y purinoceptor 1
- Platelet sensitization by LDL
- VEGFA-VEGFR2 Pathway
- activated TAK1 mediates p38 MAPK activation
- Activation of the AP-1 family of transcription factors
- KSRP (KHSRP) binds and destabilizes mRNA
- Myogenesis
- Myogenesis
- RHO GTPases Activate NADPH Oxidases
- Neutrophil degranulation
- Regulation of TP53 Activity through Phosphorylation
- CD163 mediating an anti-inflammatory response
|
- Ub-specific processing proteases
- Interleukin-4 and Interleukin-13 signaling
- RUNX1 regulates transcription of genes involved in differentiation of HSCs
- Estrogen-dependent gene expression
- Factors involved in megakaryocyte development and platelet production
|
- Dasatinib
- 4-[5-[2-(1-Phenyl-Ethylamino)-Pyrimidin-4-Yl]-1-Methyl-4-(3-Trifluoromethylphenyl)-1h-Imidazol-2-Yl]-Piperidine
- N-[(3z)-5-Tert-Butyl-2-Phenyl-1,2-Dihydro-3h-Pyrazol-3-Ylidene]-N'-(4-Chlorophenyl)Urea
- 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One
- Inhibitor of P38 Kinase
- 6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine
- 3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine
- 1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea
- 3-(Benzyloxy)Pyridin-2-Amine
- 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One
- 4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline
- 1-(5-Tert-Butyl-2-P-Tolyl-2h-Pyrazol-3-Yl)-3-[4-(2-Morpholin-4-Yl-Ethoxy)-Naphthalen-1-Yl]-Urea
- 2-Chlorophenol
- 4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole
- SB220025
- 4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE
- Triazolopyridine
- KC706
- Talmapimod
- VX-702
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
- N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide
- N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide
- Neflamapimod
- N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide
- 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE
- 4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE
- N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide
- 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE
- 4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde
- N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide
- N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide
- N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide
- PH-797804
- 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine
- 2-{4-[5-(4-chlorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-3-yl]piperidin-1-yl}-2-oxoethanol
- N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA
- N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO-
- 3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE
- 3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide
- 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE
- 3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA
- 8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM
- 2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE
- N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide
- N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide
- N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide
- 6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine
- 2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE
- [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE
- [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE
- 4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE
- 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE
- 3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE
|
|
|
|
CST6 and TGFB1 |
cystatin E/M |
transforming growth factor beta 1 |
|
- Platelet degranulation
- Influenza Virus Induced Apoptosis
- Cell surface interactions at the vascular wall
- Molecules associated with elastic fibres
- Downregulation of TGF-beta receptor signaling
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- Syndecan interactions
- ECM proteoglycans
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- TGFBR1 KD Mutants in Cancer
- TGFBR1 LBD Mutants in Cancer
- Transcriptional regulation of white adipocyte differentiation
- UCH proteinases
- Interleukin-4 and Interleukin-13 signaling
- RUNX3 regulates CDKN1A transcription
- Regulation of RUNX3 expression and activity
- RUNX3 regulates p14-ARF
|
|
- Hyaluronidase
- Hyaluronidase (Human Recombinant)
|
|
- Graft-versus-host disease
- Allograft rejection
- Camurati-Engelmann disease; Progressive diaphyseal dysplasia
|
CTBP1 and MAML2 |
C-terminal binding protein 1 |
mastermind like transcriptional coactivator 2 |
- Deactivation of the beta-catenin transactivating complex
- SUMOylation of transcription cofactors
- Repression of WNT target genes
- TCF7L2 mutants don't bind CTBP
|
- Pre-NOTCH Transcription and Translation
- Pre-NOTCH Transcription and Translation
- Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
- NOTCH1 Intracellular Domain Regulates Transcription
- NOTCH1 Intracellular Domain Regulates Transcription
- NOTCH2 intracellular domain regulates transcription
- NOTCH2 intracellular domain regulates transcription
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Notch-HLH transcription pathway
- RUNX3 regulates NOTCH signaling
- RUNX3 regulates NOTCH signaling
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH4 Intracellular Domain Regulates Transcription
- NOTCH4 Intracellular Domain Regulates Transcription
|
|
|
|
|